Previous 10 | Next 10 |
– Priority review granted, with a review goal date of June 21, 2024 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficac...
2024-02-15 07:45:00 ET Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest sum, new and seasoned investors alike can get their hands on solid co...
2024-02-11 01:45:00 ET In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working with regulatory regimes in different countries, and targeting different ...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-02-04 03:05:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Equity markets generat...
2024-01-31 15:01:32 ET More on Sarepta Therapeutics Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clin...
2024-01-30 12:25:46 ET More on PepGen PepGen: Long Road Ahead Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGen Read the full article on Seeking Alpha For further details see: ...
2024-01-29 07:53:11 ET More on Sarepta Therapeutics Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clin...
At target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20) The data support a positive benefit-risk profile for SRP-5051 Sarepta will host a conference call at 8:30 a.m. Eastern tim...
2024-01-25 09:45:00 ET Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for rare diseases or, at least, for conditions with severe un...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...
2024-06-13 15:15:01 ET Citigroup analyst issues BUY recommendation for SRPT on June 13, 2024 01:18PM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.865 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-06-13 11:00:06 ET Brian Skorney from Robert W. Baird issued a price target of $170.00 for SRPT on 2024-06-13 10:14:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $124. The overall price target consensus is at $...